IndraLab
Statements
sparser
"Then, we included the variables age, gender, clinical tumor grade, pathologic stage, lymph node status, metastasis status, and OTUD6B-AS1 mRNA level in a multivariate Cox regression model and found that the OTUD6B-AS1 mRNA level was an independent predictor for overall survival status in KIRC patients (HR = 0.275, 95% CI 0.081–0.930, p = 0.038; Table xref )."
sparser
"The upregulation of OTUD6B-AS1 expression significantly upregulated the expression of the epithelial marker E-cadherin, while the expression levels of the mesenchymal cell markers N-cadherin and Snail were downregulated in both the ACHN and OS-RC-2 cells with enhanced expression of OTUD6B-AS1 (Fig. xref c)."
sparser
"Xenograft tumors with both lncRNA OTUD6B-AS1 overexpression and As 2 O 3 treatment showed significantly weaker Ki-67 expression ( xref ) and significantly stronger p57 expression ( xref ), compared with xenograft tumors with lncRNA OTUD6B-AS1 overexpression or As 2 O 3 treatment alone."
sparser
"A total of 14 lncRNAs were identified as protective genes (AC022150.4, AC061992.1, AC090948.3, AC092794.1, AC107464.3, AL021707.8, AL451085.2, AL606834.2, FLJ42351, LINC00926, LINC01871, TNFRSF14-AS1, U73166.1 and USP30-AS1) with HRs < 1 while 10 lncRNAs (AC022150.2, AC090948.1, AC243960.1, AL021707.6, ITGB2-AS1, OTUD6B-AS1, SP2-AS1, TOLLIP-AS1, Z68871.1 and ZNF337-AS1) were associated with increased risk with HRs >1."
sparser
"Then, Kaplan-Meier analysis was used to evaluate the relationship between OTUD6B-AS1 expression in ccRCC and patient clinicopathological characteristics, and the results showed that the survival time of the patients with pathologic stage I + II disease ( n = 318) was longer than that of the patients with advanced stage lesions ( n = 205) ( P < 0.0001, Additional file xref : Figure S1A)."
sparser
"Western blotting showed that, under lncRNA OTUD6B-AS1 overexpression and As 2 O 3 treatment (20 μ mol/L), the expression of Bax and Caspase3 was significantly increased, while levels of Bcl-2 were significantly decreased relative to lncRNA OTUD6B-AS1 overexpression or As 2 O 3 treatment ( P < 0.01; Figures xref – xref )."
sparser
"Although several publications have indicated the occurrence of necroptosis regulators in KIRC, very few data are available on the involvement of lncRNAs in controlling or decreasing the neurotrophic signaling in kidney cancer, in particular based on OTUD6B-AS1, AL162377.1, AC108449.2, AF111167.2, and hsa-miR-21-5p targeting KLF9 [ xref – xref ]."
sparser
"The Wnt/β-catenin pathway is evolutionarily well-conserved, and aberrant activation of this pathway can cause abnormal cell growth and malignant transformation ( xref ; xref ). xref revealed that the novel lncRNA OTUD6B-AS1 decreased the activity of the Wnt/β-catenin pathway and suppressed the expression of EMT-related proteins."
sparser
"The results of qRT-PCR analyses showed that lncRNA OTUD6B-AS1 levels in T24 bladder cancer cells were significantly and dose-dependently increased in response to As 2 O 3 ; lncRNA OTUD6B-AS1 levels were increased by more than 8.65-fold by As 2 O 3 treatment at 20 μ mol/L for 6 h, relative to untreated T24 cells ( P < 0.01) ( xref )."
sparser
"Interestingly, following lncRNA OTUD6B-AS1 overexpression, levels of ROS and MDA in T24 cells treated with As 2 O 3 were significantly enhanced ( P < 0.01); however, the activities of the antioxidant enzymes SOD and GSH-Px showed the opposite trend, suggesting an impaired antioxidant defense system (Figures xref and xref )."
sparser
"In the field of cancer research, Wang and colleague reported OTUD6B-AS1 was downregulated in ccRCC tissue samples, and that patients with low OTUD6B-AS1 expression had shorter overall survival than patients with high OTUD6B-AS1 expression, which showed that the different expression levels of OTUD6B-AS1 indirectly correlated with patient survival ( xref )."
sparser
"To explore the role of the lncRNA OTUD6B-AS1 in ccRCC, we analyzed the expression of OTUD6B-AS1 in a cohort of 75 ccRCC tissue samples and matched nontumor samples using qRT-PCR analysis, with our results showing that OTUD6B-AS1 expression was remarkably decreased in the ccRCC tissue samples compared with the paired adjacent normal tissue samples (Fig. xref a and b)."
sparser
"In general, our study found (1) miR-26a-5p was a protective factor of breast cancer, while OTUD6B-AS1 and MTDH were risk factors; (2) OTUD6B-AS1 was the up-stream regulator of miR-26a-5p verified by luciferase; (3) up-regulation of miR-26a-5p and down-regulation of MTDH promoted cellular cytotoxicity of paclitaxel (PTX) in vitro and in vivo . (4) down-regulation of miR-26a-5p, overexpression of MTDH and OTUD6B-AS1 promoted autophagy and DNA damage; (5) up-regulation of OTUD6B-AS1 and MTDH inhibited DNA damage response (DDR) by inhibiting the phosphorylated activation of RAD51, ATR and ATM."
sparser
"Here, we found that lncRNA OTUD6B-AS1 transcription was activated by As 2 O 3 in bladder cancer cells, and these results were validated using a xenograft tumor model, suggesting that the antitumor effects of As 2 O 3 may be via upregulation of lncRNA OTUD6B-AS1; however, the roles of lncRNA OTUD6B-AS1 in exacerbated As 2 O 3 -induced oxidative damage have yet to be elucidated."
sparser
"A total of 8 immune-related lncRNAs were obtained, including OTUD6B-AS1(HR = 1.698; 95% CI 1.066–2.707, p = 0.026), AL122010.1(HR = 0.404; 95% CI 0.209–0.782, p = 0.007), AC136475.2(HR = 0.596; 95% CI 0.369–0.964, p = 0.035), AL161646.1(HR = 1.215; 95% CI 0.954–1.549, p = 0.115), AC245297.3(HR = 0.710;95% CI 0.450–1.121, p = 0.142), LINC00578(HR = 1.269; 95% CI 1.001–1.609, p = 0.049), LINC01871(HR = 0.657; 95% CI 0.448–0.964, p = 0.032), AP000442.2 (HR = 0.335; 95% CI 0.101–1.115, p = 0.075) (Fig. xref d, Table xref )."
sparser
"Additionally, 12-FRLncRNA signature involved with LINC01871, LINC00393, AC121247.2, LINC02384, LIPE-AS1, HSD11B1-AS1, AC010655.2, LINC01419, PTPRD-AS1, AC099329.2, OTUD6B-AS1, and LINC02266 could accurately predict the prognosis of patients with BC, which was confirmed by the training set, validation set, and set from GEO database."
sparser
"To corroborate these findings, we conducted ChIP assays and found that the pull-down with the MTF1 antibody greatly enriched the lncRNA OTUD6B-AS1 promoter region containing putative metal response elements (nucleotides 754 to 854 in the promoter) by almost 5.20-fold relative to control IgG ( P < 0.01), and a reference region (nucleotides 100 to 200 in the promoter) without putative MRE was used as a negative control ( xref ."
sparser
"We calculated the risk scores for all samples using the following formula: Risk score = (0.309031851 × Exp of TDRKH-AS1) + (0.213481355 × Exp of AC011978.2) + (0.170772984 × Exp of AC110995.1) + (0.051734285 × Exp of OTUD6B-AS1) + (0.046646469 ×Exp of YTHDF3-AS1) + (0.019875191 × Exp of AL512380.1) + (0.019087737 × Exp of MIR4435-2HG) + (–0.037067764 × Exp of HSD11B1-AS1) + (–0.063799579 × Exp of LINC02084) + (–0.162152639 × Exp of TRG-AS1) + (–0.399031951 × Exp of AL451085.3) + (–0.886350422 × Exp of AL109955.1)."
sparser
"Using these HRLs, we finally constructed a novel prognostic model for patients with breast cancer, which consisted of 12 PHRLs: TDRKH-AS1, AC011978.2, AC110995.1, OTUD6B-AS1, YTHDF3-AS1, AL512380.1, MIR4435-2HG, HSD11B1-AS1, LINC02084, TRG-AS1, AL451085.3, and AL109955.1 (RBM38-AS1)."
sparser
"In this study, we found that the expression of the lncRNA OTUD6B-AS1 was downregulated in ccRCC tissue samples and that patients with low OTUD6B-AS1 expression had shorter overall survival than patients with high OTUD6B-AS1 expression, which showed that the different expression level of OTUD6B-AS1 indirectly correlated with survival of patients."
sparser
"In conclusion, to the best of our knowledge, the present study was the first to investigate the role of OTUD6B-AS1 in CRC cells, and to reveal that lncRNA OTUD6B-AS1 overexpression inhibited the proliferation, invasion and migration of HCT116 cells, at least partially, by targeting miR-3171."
sparser
"In a series of assays, it was observed that the additional treatment with miR-3171 mimics following OTUD6B-AS1 overexpression in HCT116 cells promoted the proliferation, invasion and migration of HCT116 cells, suggesting that OTUD6B-AS1 overexpression inhibited the proliferation, invasion and migration of HCT116 cells via downregulation of miR-3171 expression."
sparser
"We identified 15 antisense lncRNAs ( RUSC1-AS1 , TBX2-AS1 , PTOV1-AS1 , UBE2D3-AS1 , ERCC8-AS1 , ZMIZ1-AS1 , RNF144A-AS1 , RDH10-AS1 , TRG-AS1 , GSN-AS1 , HMGA2-AS1 , ZNF528-AS1 , OTUD6B-AS1 , COX10-AS1 and SLC16A1-AS1 ) that were upregulated in tumour samples compared to bone sample controls."